|Application ||DB, E|
|Other Accession||Q9N077, NP_115542.2|
|Calculated MW||85838 Da|
|Other Names||ATR-interacting protein, ATM and Rad3-related-interacting protein, ATRIP, AGS1|
|Target/Specificity||This ATRIP Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S239 of human ATRIP.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Phospho-ATRIP(S239) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Required for checkpoint signaling after DNA damage. Required for ATR expression, possibly by stabilizing the protein.|
|Cellular Location||Nucleus. Note=Redistributes to discrete nuclear foci upon DNA damage|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The product of this gene is an essential component of the DNA damage checkpoint, and binds to single-stranded DNA coated with replication protein A that accumulates at sites of DNA damage. The encoded protein interacts with the ataxia telangiectasia and Rad3 related protein, a checkpoint kinase, resulting in accumulation of the kinase at intranuclear foci induced by DNA damage. Multiple transcript variants encoding different isoforms have been found for this gene.
Bailey, S.D., et al. Diabetes Care (2010) In press :
Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
Vega, A., et al. Gynecol. Oncol. 112(1):210-214(2009)
Myers, J.S., et al. Cancer Res. 67(14):6685-6690(2007)
Venere, M., et al. Cancer Res. 67(13):6100-6105(2007)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.